Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1119)	12/12/1998 6:01:00 PM
From: Elmer Flugum	Read Replies (2) \| Respond to of 1580

The highly lucrative MERCK product brand name MEVACOR (natural substance named Lovastatin) looses patent protection soon. Merck stands to loose substantial revenues due to this. Yet, its widely know, as shown by the study below, done in 1992, and published in the British Journal of Cancer, the MEVACOR (lovastatin) when used in combination with another drug, ONCONASE, offers potent anti-cancer action. Yet, no action has been taken to develop this. As Mevacor starts to loose revenue as a cholesterol lowering drug, hopefully, Merck will finally wake up to profiting from the anti-cancer uses of MEVACOR (Lovastatin), which has been known for many years. DEMAND MERCK WAKE UP AND SMELL THE COFFEE (or loose a lot of profit and potential.) It also might be nice to know WHY? WHY? WHY they haven't acted on this before now. Shareholders deserve some real, no b*llshit answers to this one. All responses to go to: cocktailtime@yahoomail.com